141 related articles for article (PubMed ID: 11275703)
1. Management of breast cancer: is there a role for somatostatin and its analogs?
Boccardo F; Amoroso D
Chemotherapy; 2001; 47 Suppl 2():62-77. PubMed ID: 11275703
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin receptors and breast cancer.
Cameron Smith M; Orlando C; Serio M; Maggi M
J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228
[No Abstract] [Full Text] [Related]
4. Biology of somatostatin in breast cancer.
Watt HL; Kharmate G; Kumar U
Mol Cell Endocrinol; 2008 May; 286(1-2):251-61. PubMed ID: 18308465
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin, its receptors and analogs, in lung cancer.
O'Byrne KJ; Schally AV; Thomas A; Carney DN; Steward WP
Chemotherapy; 2001; 47 Suppl 2():78-108. PubMed ID: 11275704
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
Hasskarl J; Kaufmann M; Schmid HA
Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs for cancer treatment and diagnosis: an overview.
Scarpignato C; Pelosini I
Chemotherapy; 2001; 47 Suppl 2():1-29. PubMed ID: 11275699
[TBL] [Abstract][Full Text] [Related]
8. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
9. Rationale for treating cancer with somatostatin analogs.
Minuto F; Ferone D; Arvigo M; Barreca A
J Endocrinol Invest; 2003; 26(8 Suppl):117-9. PubMed ID: 15233226
[No Abstract] [Full Text] [Related]
10. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs in oncology: a look to the future.
Jenkins SA; Kynaston HG; Davies ND; Baxter JN; Nott DM
Chemotherapy; 2001; 47 Suppl 2():162-96. PubMed ID: 11275709
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
13. Role of somatostatin analogs in the management of rare tumors and diseases.
Palmieri G; Montella L
J Endocrinol Invest; 2003; 26(8 Suppl):89-91. PubMed ID: 15233221
[No Abstract] [Full Text] [Related]
14. The role of somatostatin analogs in the management of prostate cancer.
Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
[No Abstract] [Full Text] [Related]
15. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
16. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
Kvols LK; Woltering EA
Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
[TBL] [Abstract][Full Text] [Related]
17. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
18. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative effect of somatostatin and analogs.
Bousquet C; Puente E; Buscail L; Vaysse N; Susini C
Chemotherapy; 2001; 47 Suppl 2():30-9. PubMed ID: 11275700
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.
de Herder WW; Lamberts SW
Endocrine; 2003 Apr; 20(3):285-90. PubMed ID: 12721509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
